Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(11%)
Results Posted
114%(8 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
1
11%
Ph phase_3
3
33%
Ph not_applicable
1
11%
Ph phase_4
3
33%
Ph phase_2
1
11%

Phase Distribution

1

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
3(33.3%)
Phase 4Post-market surveillance
3(33.3%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 21 (11.1%)
Phase 33 (33.3%)
Phase 43 (33.3%)
N/A1 (11.1%)

Trials by Status

completed778%
terminated111%
active_not_recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
active_not_recruitingphase_1

Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older

NCT06851832
terminatednot_applicable

Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination

NCT02590068
completedphase_4

Immune Response to Shingles Vaccination

NCT02624375
completedphase_3

Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

NCT01527370
completedphase_3

Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

NCT01245751
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06851832Phase 1

Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older

Active Not Recruiting
NCT02590068Not Applicable

Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination

Terminated
NCT02624375Phase 4

Immune Response to Shingles Vaccination

Completed
NCT01527370Phase 3

Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

Completed
NCT01245751Phase 3

Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

Completed
NCT01556451Phase 4

ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)

Completed
NCT00550745Phase 4

ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

Completed
NCT01505647Phase 3

Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)

Completed
NCT00546819Phase 2

ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9